Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
NCT02544022 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 476
Last updated 2026-04-24
Summary
Background:
People with neurofibromatosis 1 (NF1) who have plexiform neurofibromas (pNFs) can have pain that affects their daily lives. This study aims to improve questionnaires that measure their pain, daily living, and physical functioning.
Objectives:
To examine and improve questionnaires about daily living for people with NF1 and pNFs.
Eligibility:
People ages 5 and older with NF1 and a pNF
Design:
Participants will be screened with medical history.
This study will have 2 phases.
Phase 1 participants will talk about existing pain assessment questionnaires and how pNFs affect their life. They will have group discussions of up to 8 people of a similar age with NF1 and pNFs, or the parents of children with it. These will last about 90 minutes. Children ages 5 to 7 and their parents will have one-on-one meetings instead. These will last about 45 minutes. Discussions will be audiotaped. After the questionnaires have been changed, individual interviews will discuss the new wording, instructions, questions, and electronic format of the new forms.
Phase 2 is now complete.
Phase 1 participants may be invited to Phase 2.
Phase 2 participants will complete the new questionnaires. These may be pen-and-paper or electronic. The questionnaires will take about 30 minutes for adults and teens. Children will work one-on-one with a staff member and may need up to 45 minutes. A small group of participants will be complete the forms twice-in clinic and 1 month later at home. Also, a small group who start a new pain treatment or have a dose increase in their treatment will complete the forms twice-before the treatment change and 1 month later.
Conditions
- Neurofibromatosis 1
- Plexiform Neurofibromas
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Pamela L Wolters, Ph.D. · National Cancer Institute (NCI)
Eligibility
- Min Age
- 5 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-11-13
- Primary Completion
- 2026-06-30
- Completion
- 2026-12-31
Countries
- United States
Study Locations
More Related Trials
-
Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
NCT02435628 ·Status: COMPLETED
-
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
NCT05677594 ·Status: ACTIVE_NOT_RECRUITING
-
Natural History Study of Patients With Neurofibromatosis Type I
NCT00924196 ·Status: ACTIVE_NOT_RECRUITING
-
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
NCT06379230 ·Status: RECRUITING
-
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
NCT02101736 ·Status: COMPLETED ·Phase: PHASE2
-
Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1
NCT00314119 ·Status: COMPLETED
-
Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients
NCT01218139 ·Status: UNKNOWN
-
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
NCT06507748 ·Status: RECRUITING ·Phase: NA
-
Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial
NCT04879160 ·Status: COMPLETED
-
Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1
NCT05199376 ·Status: RECRUITING ·Phase: NA
-
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
NCT03820778 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of PEG-Intron for Plexiform Neurofibromas
NCT00396019 ·Status: COMPLETED ·Phase: PHASE2
-
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Reliability of Functional Outcome Measures in Neurofibromatosis 1
NCT02479360 ·Status: COMPLETED
-
Reliability of Functional Outcome Measures in Neurofibromatosis 2
NCT03617276 ·Status: COMPLETED
-
PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma
NCT00253474 ·Status: COMPLETED ·Phase: PHASE1
-
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
NCT01800032 ·Status: COMPLETED
-
Neurofibromatosis Type 1 Patient Registry
NCT01410006 ·Status: COMPLETED
-
Natural History Study of Patients With Neurofibromatosis Type 2
NCT00598351 ·Status: RECRUITING
-
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
NCT00060008 ·Status: TERMINATED ·Phase: NA
-
Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma
NCT07226453 ·Status: RECRUITING ·Phase: PHASE2
-
Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
NCT02387840 ·Status: TERMINATED ·Phase: NA
-
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
NCT01222728 ·Status: COMPLETED
-
A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I
NCT04461886 ·Status: TERMINATED ·Phase: PHASE3
-
Peripheral Primitive Fibromatosis
NCT01801176 ·Status: COMPLETED ·Phase: NA